SCHEMBL983811

SCHEMBL983811

CNC(=O)c1cc2cc(C3(Cc4ccccc4)CCN(Cc4ccccc4)C3)ccc2[nH]1

nearest known ligand 0.69

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 5/20 0.69
SLC6A2 P23975 5/20 0.69
SLC6A4 P31645 5/20 0.69
SLC6A3 Q01959 5/20 0.69
NAMPT P43490 1/20 0.45
PYGL P06737 5/20 0.43
KDM4E B2RXH2 2/20 0.42
KMT2A Q03164 1/20 0.42
ACHE P22303 1/20 0.42
BACE1 P56817 1/20 0.42
GPR183 P32249 1/20 0.41
KCNH2 Q12809 1/20 0.40
ALOX15 P16050 1/20 0.40
NR3C1 P04150 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL980898 0.87 CYP2D6 (0.69) CYP2D6SLC6A2SLC6A4SLC6A3NAMPT
SCHEMBL982962 0.85 CYP2D6 (0.52) CYP2D6SLC6A2SLC6A4SLC6A3KDM4E
SCHEMBL980803 0.82 SLC6A2 (1.00) CYP2D6SLC6A2SLC6A4SLC6A3PYGL
SCHEMBL2879409 0.79 SLC6A2 (0.64) CYP2D6SLC6A2SLC6A4SLC6A3GPR183
SCHEMBL984260 0.75 SLC6A2 (0.63) CYP2D6SLC6A2SLC6A4SLC6A3KDM4E
SCHEMBL980929 0.74 CYP2D6 (0.64) CYP2D6SLC6A2SLC6A4SLC6A3KDM4E
SCHEMBL984635 0.72 CYP2D6 (0.62) CYP2D6SLC6A2SLC6A4SLC6A3KDM4E
SCHEMBL982965 0.72 SLC6A2 (0.81) CYP2D6SLC6A2SLC6A4SLC6A3KDM4E
SCHEMBL981298 0.71 NR3C1 (0.48) CYP2D6KDM4EKMT2ANR3C1
SCHEMBL981130 0.71 OPRM1 (0.53) CYP2D6KDM4EKMT2ABACE1NR3C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2257545-B1 PYRROLIDINYL DERIVATIVES AND USES THEREOF HOFFMANN LA ROCHE (CH) 2011-08-31 EP disclosed
EP-2257545-B1 PYRROLIDINYL DERIVATIVES AND USES THEREOF HOFFMANN LA ROCHE (CH) 2011-08-31 EP disclosed
US-20110021556-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF HOFFMAN-LA ROCHE, INC. (US) 2011-01-27 US disclosed
US-20110021556-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF HOFFMAN-LA ROCHE, INC. (US) 2011-01-27 US disclosed
US-20110021556-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF HOFFMAN-LA ROCHE, INC. (US) 2011-01-27 US disclosed
EP-2257545-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF F. Hoffmann-La Roche AG (CH) 2010-12-08 EP disclosed
WO-2009115427-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2009-09-24 WO disclosed
WO-2009115427-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF F. HOFFMANN-LA ROCHE AG (CH) 2009-09-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021556-A1 PYRROLIDINYL DERIVATIVES AND USES THEREOF SLC6A3, MAOB, TPH2 CYP2D6 97/4885SLC6A2 6/4885SLC6A4 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.